Verona Pharma plc — Director's Dealing 2023

Aug 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2023-08-01

Reporting Person: Hahn Mark W (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-08-01	Ordinary Shares	S	105944	$2.679	Disposed	15870840	Direct
2023-08-02	Ordinary Shares	S	73704	$2.593	Disposed	15797136	Direct

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction entered into on March 24, 2022 solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units.

F3: The price reported represents the sale price of the ADSs divided by eight (8).

F4: Consists of (i) 5,911,816 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 738,977 ADSs); and (ii) 9,885,320 Ordinary Shares underlying 1,235,665 ADSs.